NovoCure Limited

NASDAQ: NVCR · Real-Time Price · USD
11.82
0.23 (1.98%)
At close: Aug 15, 2025, 12:50 PM

NovoCure Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
605.22M 509.34M 537.84M 535.03M
Cost of Revenue
137.18M 128.28M 114.87M 114.88M
Gross Profit
468.04M 381.06M 422.97M 420.15M
Operating Income
-170.5M -232.87M -89.52M -44.33M
Interest Income
51M 46.04M 10.96M 791K
Pretax Income
-131.16M -191.74M -81.85M -52.08M
Net Income
-168.63M -207.04M -92.53M -58.35M
Selling & General & Admin
428.89M 390.87M 306.41M 263.18M
Research & Development
209.65M 223.06M 206.09M 201.3M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
638.53M 614.67M 512.5M 464.49M
Interest Expense
11.66M 4.91M 3.33M 3.44M
Selling & Marketing Expenses
239.06M 226.81M 173.66M 137.06M
Cost & Expenses
775.72M 742.21M 627.36M 579.36M
Income Tax Expense
37.47M 15.3M 10.69M 6.28M
Shares Outstanding (Basic)
107.83M 106.39M 104.66M 103.43M
Shares Outstanding (Diluted)
107.83M 106.39M 104.66M 103.43M
EPS (Basic)
-1.56 -1.95 -0.88 -0.56
EPS (Diluted)
-1.56 -1.95 -0.88 -0.56
EBITDA
-108.26M -175.87M -63.11M -38.38M
EBIT
-120.82M -188.42M -78.51M -48.63M
Depreciation & Amortization
11.23M 10.97M 10.62M 10.25M